Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 June 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Natalizumab Phase II data show promising results in Crohn's disease

Natalizumab (Antegren), a humanized monoclonal antibody, demonstrated promising results in a Phase II study of Crohn's Disease, according to data presented at the annual meeting of the American Gastroenterological Association during Digestive Disease Week.

News image

fiogf49gjkf04

Natalizumab is an alpha-4 integrin inhibitor that is designed to prevent migration of inflammatory cells from blood vessels to the site of inflammation. Elan Corporation plc and Biogen Inc. are collaborating on the development of natalizumab.

The study enrolled 244 moderate to severely active patients with Crohn's Disease (Crohn's Disease Activity Index ('CDAI') score 220-450), from 38 sites in 8 countries.

The data was reported on 23 May 2001 to the DDW meeting, held in Atlanta, Georgia, USA.

The patients were randomized to one of four treatment groups. These were: a single 3 mg/kg natalizumab infusion; two 3 mg/kg natalizumab infusions at a 4-week interval; two 6 mg/kg natalizumab infusions at a 4-week interval; or placebo.

Proportion of patients achieving remission:
3 mg/kg natalizumab: 46%
Placebo: 27%
Elan Corporation

Patients were followed for 12 weeks following the first infusion and were assessed using the CDAI and changes in quality of life, as assessed by the Inflammatory Bowel Disease Questionnaire ('IBDQ').

A statistically significant difference in clinical response (decrease of more than 70 points in CDAI) was noted as early as Week 2 and was maintained through Week 12. The researchers observed a maximal response of 74% in the 3 mg/kg-dose group versus 38% in the placebo group.

Remission, defined as a CDAI score of less than 150, was achieved by 46% of patients in the 3 mg/kg dose group versus 27% in the placebo group.

There was also a statistically significant difference in the change from baseline IBDQ score in patients receiving two infusions of natalizumab as compared to those receiving placebo at both Week 6 and Week 12.

In this trial natalizumab was generally well tolerated. Data suggests that the most common adverse events reported were headache and abdominal pain. There were no notable differences among treatment groups in the number of patients reporting side-effects.

Phase III studies are expected later this year.

The study's lead investigator, Professor Paul Rutgeerts of the Department of Endoscopy, Universitaire Ziekenhuizen Leuven, Belgium, said, "Many existing therapies have problematic side-effects, or have questions concerning safety with long-term use; therefore, other therapies are needed to treat this disease."

"The Phase II data are exciting because they show, for the first time, that this novel humanized monoclonal antibody may provide an effective treatment to induce remission and maintenance of Crohn's Disease," he concluded.

Elan Corporation, plc 23 May 2001
04 June 2001

Go to top of page Email this page Email this page to a colleague

 31 May 2018 
Diagnostic for NAFLD  
 31 May 2018 
Bile acids and the risks for hepatotoxicity
 31 May 2018 
Rectal cancer female sexuality score
 30 May 2018 
Fungal dysbiosis in cirrhosis
 30 May 2018 
Placebo rates in ulcerative colitis trials
 30 May 2018 
Follow-up testing and colorectal cancer mortality
 29 May 2018 
Organ transplantation donors
 29 May 2018 
Novel therapies for IBD
 29 May 2018 
Helicobacter pylori infection to stomach cancer
 28 May 2018 
Mesalazine in ulcerative colitis
 28 May 2018 
Technology and management of digestive diseases
 28 May 2018 
Therapeutic strategies for HCV
 25 May 2018 
Post‐operative complications in elderly IBD
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Colorectal cancer–specific mortality
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Chronic Hep B
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Symptom assessment in cirrhotic ascites
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
European guidelines on pancreatic cystic neoplasms

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us